Temozolomide (TMZ) induces GBM cell death via introducing DNA methylation on purine bases and its efficacy is heavily influenced by molecular factors such as O-6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation with patients having higher methylation showing better response. This evidence concerns the gene MGMT and glioblastoma.